Bronchodilator therapy
- Breathlessness is multifactorial in bronchiectasis.
- A trial of combination bronchodilator containing a long-acting beta2agonist (LABA) and long-acting muscarinic antagonist (LAMA) can be considered, particularly if the patient has co-existent COPD.
- The choice of LABA/LAMA should be based on the inhaler technique of the patient, local and national prescribing guidance.